<PAGE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED OCTOBER 31, 1995 COMMISSION FILE NO. 0-7100
BASE TEN SYSTEMS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
NEW JERSEY 22-1804206
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
ONE ELECTRONICS DRIVE
TRENTON, NEW JERSEY 08619
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (609) 586-7010
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
Class A Common Stock Nasdaq National Market
Class B Common Stock Nasdaq
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes X No
--- ---
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of Regulation S-K under the Securities Exchange Act of 1934 is not contained
herein, and will not be contained, to the best of the Registrant's knowledge, in
definitive proxy or information statements incorporated in Part III of this Form
10-K or any amendments to this Form 10-K. [ ]
As of December 31, 1995, 7,244,495 shares of Class A Common Stock and 458,474
shares of Class B Common Stock were outstanding, and the aggregate market value
of shares held by unaffiliated stockholders was approximately $77,671,088 and
$2,722,499, respectively.
DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the Proxy Statement for the 1996
Annual Meeting of Shareholders are incorporated by reference into
Part III of this Report.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
PART I
ITEM 1. BUSINESS
INTRODUCTION
GENERAL. Base Ten Systems, Inc. ("Base Ten" or the "Company") is engaged
in the design and manufacture of electronic systems employing safety critical
software for defense markets and the development of commercial applications
focused on batch processing control, medical screening and image processing
software. The Company also manufactures defense products to specifications for
prime government contractors and designs and builds proprietary electronic
systems for use in secure communications by various U.S. government agencies.
Specialization in extreme reliability defense products has enabled the
Company to develop expertise in the field of safety critical technology
dedicated to the prevention of performance errors. Operations in this
environment during the last two decades have also provided experience in
developing advanced quality control procedures for products meeting stringent
government standards as well as familiarity with complex government regulations
and agency procedures. Over the last several years, Base Ten has redirected
resources to decrease its historical dependence on defense contracting and has
concentrated on commercial products for highly regulated industries, relying on
the same safety critical techniques developed in its traditional businesses.
While the Company's nondefense programs involve major potential markets, the
resulting products are still primarily developmental and may not succeed in
reaching their potential.
CHANGE IN BUSINESS DIRECTION. Since 1976, the Company's principal business
has been the development of weapons control systems for the West German and
Italian versions of the Tornado multirole combat aircraft and, more recently,
for the U.S. Department of Defense. Beginning in 1990, Base Ten experienced
sharp declines in sales and profitability resulting from significant reductions
in military defense expenditures. In response to these conditions, the Company
implemented a plan for redeployment of its resources and reduction of its fixed
costs. Under this program, various operations were discontinued, and the
Company's labor force was substantially reduced. At the same time, Base Ten
commenced development of nondefense products utilizing its electronic systems
engineering capabilities, experience in designing high reliability, safety
critical software and ability to manufacture developed products to stringent
quality standards.
These efforts have included the development of manufacturing execution
software to control batch processing functions and reduce costs for
pharmaceutical and other regulated manufacturers. Sales to several of the
pharmaceutical industry's largest participants were made during 1995. Base Ten
has also concentrated on medical software to facilitate laboratory or clinician
screening and diagnostic tests that may ultimately assist in identifying a wide
range of diseases at early stages with greater accuracy and less cost than
current testing procedures. Regulatory approval was obtained in 1995 for
domestic sales of the Company's first medical screening software product.
During the last two years, the Company has expanded its medical software to
include image capture and storage systems for ultrasound images. In addition,
Base Ten has developed a series of products involving secure communications for
government users and ultimately for commercial applications. While these
proprietary products could be expected to provide more favorable profit margins
than the Company's defense business, development has been funded internally, and
limited financial resources along with various regulatory hurdles could
adversely affect the timing and success of marketing efforts.
Base Ten regards its nondefense products as the primary source of future
growth and has directed a significant part of its business effort to these
development projects. To date, however, the Company remains dependent on
defense markets for most of its revenues, and it has continued to devote
resources to the defense sector, including development of new products for
military applications. Base Ten intends to maintain its position in the weapons
control market while continuing the development of new products with commercial
or industrial applications, relying on its electronic engineering and software
skills as well as its extensive experience with safety critical products and
systems to differentiate itself from its competitors.
MANUFACTURING EXECUTION AND MEDICAL SOFTWARE PRODUCTS
GENERAL. The Company's Medical Technology Division is engaged in the
development of software systems for the healthcare and other regulated
industries. Base Ten's strategy for its Medical Technology Division has
involved the use of its safety critical software technology to process data with
greater accuracy, speed and reliability but at less cost than current procedures
in fields targeted by the Company. These fields were selected for their
importance and rapid growth as well as their logical fit with the Company's
established technology. They include manufacturing execution systems for
pharmaceutical and other regulated industries, computer aided test
interpretation (CATI) for identifying patients with particular diseases at an
early stage and image capture and storage
1
<PAGE>
systems for ultrasound images.
MANUFACTURING EXECUTION SYSTEMS. During 1993, Base Ten began development
and marketing activities on PHARMASYST-TM-, a proprietary program applying
safety critical techniques to a manufacturing execution system. The system was
designed to assist pharmaceutical manufacturers in containing costs and meeting
the Current Good Manufacturing Practices (CGMP) required by the Food and Drug
Administration (FDA) for the quality of pharmaceuticals and the integrity of
data that support their safety and effectiveness. The system supports the
manufacturer's compliance with CGMP requirements governing inspection
procedures, controls, storage, handling, sampling, testing and disposal for each
pharmaceutical batch, along with associated recordkeeping requirements, while
also providing a means for reducing manufacturing costs and improving
productivity.
The Company's initial sale of PHARMASYST-TM- was made during 1993 to
Clonmel Health Care, Ltd., a leading Irish pharmaceutical manufacturer. In
early 1994, Clonmel agreed to expand the use of PHARMASYST-TM- to include
manufacturing procedures for its veterinary health care products at its VetPharm
facility in Dublin, Ireland. During 1994, as the potential for broader
PHARMASYST-TM- applications became apparent in the course of the initial Clonmel
installation, the Company devoted additional development efforts to the system,
extending the completion date for the Clonmel installation into the first
quarter of 1995. This schedule has been further extended into 1996 to
incorporate more advanced features and updated designs. Clonmel has agreed to
use the installed system as both a pilot operation and a demonstration facility
to assist in marketing PHARMASYST-TM- throughout the European Economic
Community.
In addition to these efforts, the Company has dedicated substantial
engineering and sales resources to introduce its PHARMASYST-TM- program to a
potentially large domestic market influenced by current FDA pressures and cost
sensitivity. The first PHARMASYST-TM- sale in the United States was recorded in
December 1994 to Miles Pharmaceuticals (now Bayer) in Berkeley, California.
Additional sales were made during 1995 to Abbott Hospital Products Division,
Pfizer International Products Group, Minnesota Mining and Manufacturing,
Nycomed, Berlex and others.
Base Ten believes that the current FDA policy to shut down pharmaceutical
manufacturers without adequate processing controls and the increasing pressure
for cost containment offers growth opportunities for PHARMASYST-TM- that were
previously unavailable in this market. As of the date of this Report, Base Ten
has received bookings and notifications of its selection by pharmaceutical
companies expected to result in PHARMASYST-TM- installations in over 30 sites
throughout the world. The Company has significantly increased its technical
staff and facilities to accommodate anticipated growth in this field and is
actively pursuing additional sales to the pharmaceutical industry, both
domestically and abroad. The shift in resources to exploit these opportunities
can be expected to have an adverse impact on the Company's financial results
until PHARMASYST-TM- sales increase.
To allow the broadest market applicability, PHARMASYST-TM- was designed as
a modular, open architecture PC-based system that can be applied in a wide
variety of manufacturing environments. In addition to pharmaceuticals, these
applications include chemicals, medical devices, cosmetics, food products,
beverages and consumer package goods. During 1995, initial sales of PHARMASYST-
TM- outside the pharmaceutical industry were made to Frito Lay. The Company
plans to exploit the flexibility of the PHARMASYST-TM- system with expanded
marketing efforts in a variety of regulated industries during 1996.
MEDICAL SCREENING SOFTWARE. The Company's Medical Technology Division has
created three software programs to aid in the detection of risk for particular
birth defects. The first two programs are designed to accelerate the
computation of risk detection for neural tube defects (PRENVAL-TM- I) and Down's
syndrome (PRENVAL-TM- IA) in pregnant women. Both of these programs evaluate
the levels of alpha-feto protein (AFP) in maternal serum against normal
reference ranges while making laboratory directed adjustments for factors
including the patient's age, weight, race, diabetic status and state of
pregnancy. The third program (PRENATA-TM-) employs additional markers and
advanced statistical methods to increase the accuracy and user friendliness of
risk detection tests for both these birth defects. A portion of this program
has been sold and the remainder licensed to the Johnson & Johnson Clinical
Diagnostic Division (J&J), located in Amersham, England. J&J offers PRENATA-TM-
in connection with the sale of its products used in the detection of fetal
abnormalities throughout the world except for the United States. The Company's
agreement with J&J provides for guaranteed minimum royalties for a period of
five years beginning in October 1994.
2
<PAGE>
Although the PRENVAL-TM- programs involve noninvasive testing procedures,
the FDA published guidelines in 1991 requiring this type of medical software
package to receive FDA clearance prior to sales in the United States. PRENVAL-
TM- I was initially submitted to the FDA under these guidelines in August 1992.
The submission was the first of its kind and was reviewed by the FDA from
aspects of both software and a medical device. Upon completing its compilation
of clinical data in April 1993, Base Ten submitted its definitive premarket
approval application (PMA) for PRENVAL-TM- I and believed that it had complied
with the FDA's expanded requirements, which are similar to the military software
specifications for the Company's safety critical defense products.
In January 1994, the FDA requested additional clinical data taken
prospectively. This data was submitted in April 1994. The Company was advised
in September 1994 that its PMA had been accepted for filing, a necessary step to
achieve final approval. The Company's PMA was presented to an Advisory Panel
convened by the FDA in March 1995. The Panel voted 5 to 3 to deny approval of
the PMA on the grounds that PRENVAL-TM- should not be classified as a medical
device.
The FDA subsequently chose to classify PRENVAL-TM- I as a Class 1 Tier 3
medical device and granted the Company permission to market the device beginning
in September 1995. Under the direction of the FDA, PRENVAL 1 was relabeled to
an intended use as a software computer program to assist in the database
management, calculation of the Multiple of the Median (MoM) and generation of
reports from the quantitative measurement of AFP. This definition of intended
use broadened the application of PRENVAL-TM- 1 to include any prenatal
abnormality in which AFP was used to calculate the MoM, eliminating the need for
PRENVAL-TM- 1A.
Unlike PRENVAL-TM-, the Company's PRENATA-TM- software licensed to J&J
processes the results of certain blood tests that use reagents not yet approved
by the FDA but is intended for sale only outside the United States. The Company
plans to seek FDA approval of PRENATA-TM- or a similar program for sale in the
United States only if a suitable marketing partner can be found and the cost of
clinical trials does not provide an obstacle.
The Company considers its existing PRENVAL-TM- software to be initial
products in a series of clinical diagnostic tests needed in the healthcare
industry. The FDA is now applying standards, procedures and policies for
medical software based in part on the regulation of safety critical software by
other federal agencies and in part on discussions now being held with industry
participants. The Company believes its broad experience in developing software
for the defense industry in compliance with these standards is particularly
suited to the CATI market and provides Base Ten with a competitive advantage in
developing products for this market. Despite this advantage, the Company has
temporarily delayed applying further resources to this product line to exploit
the greater near term potential of its PHARMASYST-TM- systems and potentially
benefit from current discussions and hearings by the FDA on its medical software
regulations, any simplification of which could enable the Company to complete
future medical software products at lower costs.
MEDICAL OPERATING SOFTWARE. FDA approval requirements for medical software
have prompted the Company to begin development of a computer operating shell
(MED-DOS-TM-) embodying safety critical software techniques to verify that a
computer processing medical software is functioning as intended. The MED-DOS-
TM- operating shell is intended for use with a conventional operating system to
detect and record errors or deviations and either correct them in real time or
halt the program, transforming a conventional computer into a safety critical
device. Base Ten has also begun work on a companion system to provide software
authors and programmers an environment for developing safety critical software
meeting FDA requirements. By detecting computer errors and helping to format
software for FDA compliance, MED-DOS-TM- could offer substantial advantages in
developing new medical software or converting existing medical software to
comply with those requirements.
The Company has filed three patent applications covering separate aspects
of its MED-DOS-TM- technology. The basic patent for MED-DOS-TM- was granted to
Base Ten in 1994, and allowances for the other two applications were received in
1995. The need for a safety critical methodology to satisfy FDA controls could
position MED-DOS-TM- to influence the entire medical software field and become
an important factor in the Company's prospects. Despite this potential,
completion of the MED-DOS-TM- software products will require additional funding
and participation by a suitable marketing partner. Development efforts have
been suspended to concentrate resources on PHARMASYST-TM- and evaluate
anticipated regulatory changes in this area.
ULTRASOUND IMAGING PRODUCTS. Base Ten has developed an archiving system
for ultrasound images (uPACS) as a methodology for digitizing, recording and
permanently storing ultrasound images on CD-ROMs,
3
<PAGE>
with the potential for replacing the existing methodology using Polaroid film or
video recording systems. The Company's system employs a video capture computer
card that electronically converts the video output of an ultrasound scanner into
a digital format on a CD-ROM for long term storage and convenient access, a
feature not available with either video tape or Polaroid film. Base Ten has
begun to market this product outside the United States, with domestic
introduction subject to FDA approval. The Company plans to file a 510K
premarket notification application for uPACS with the FDA in early 1996.
Despite substantial competition on both price and features in this field,
Base Ten believes its uPACS product has benefits that make further development
and marketing efforts worthwhile. The Company also believes it has achieved an
advantage over smaller competitors in the EEC through a CE mark for uPACS,
representing a self certification of quality and performance required by
regulatory bodies. The Company is currently pursuing sales opportunities in
Europe through distributors, while also seeking alliances with OEM manufacturers
and major users of ultrasound systems. To facilitate these efforts, Base Ten
plans to introduce a networking feature for uPACS, reducing the cost of the
system relative to the number of ultrasound scanners being served.
CONSULTING ARRANGEMENTS. The Company has a consulting arrangement with Dr.
Laurence M. Demers, Director of Clinical Laboratories with the Hershey Medical
Center. Dr. Demers is the President-elect of the American Clinical Chemistry
Association and scientific advisor to several major pharmaceutical companies.
The arrangement provides for evaluations and recommendations on medical software
development projects. Base Ten believes Dr. Demers' technical and strategic
contributions have assisted in refining existing products, stimulating new
product ideas and broadening the scope of potential opportunities for
applications of the Company's safety critical technology.
MILITARY PRODUCTS
TORNADO PARTICIPATION. The Company has historically concentrated on the
design and production of weapons control systems produced for the West German
and Italian versions of the Tornado aircraft. These systems are designed to aid
the operator of a sophisticated combat aircraft in deploying its highly complex
weapons. The Tornado program is a joint program of the German, United Kingdom
and Italian governments for a multirole combat aircraft meeting the requirements
of the particular environmental conditions in western Europe. Base Ten's
participation in Tornado programs has also included contracts to supply certain
elements of the system to British Aerospace for sales to the Saudi Arabian Air
Force.
The most important and complex weapons control system manufactured by the
Company for the Tornado program is the Stores Management System (SMS). The SMS
employs a visual display to communicate the current status of weapons on board
the aircraft to the operator. It permits the operator to select appropriate
weapons, to confirm or change the selection of weapons and to execute other
functions such as weapon jettison and fault detection. All of these actions are
regulated by a weapons programming unit containing the microprocessor and its
memories. The SMS has up to seven electronic units, remotely located from the
weapons programming unit, to receive and decode release instructions and
activate switches connected to weapon release mechanisms.
Base Ten manufactures the SMS for the Tornado program under a contract with
Daimler-Benz Aerospace AG, a German aerospace manufacturer (DASA). In fiscal
1995, 1994 and 1993, sales to DASA accounted for approximately 26%, 22% and
18%, respectively, of the Company's total sales. In 1995, the Company received
full funding for additional production of weapons control products for the
Tornado program under contracts valued at approximately $6.3 million. This
contract is expected to be completed in 1996. In the first quarter of fiscal
1996, initial funding was received for Tornado software upgrades under a
contract valued at $1.8 million extending into 1997.
OTHER PROGRAMS. Base Ten has applied its weapons control systems
technology to Sidewinder air-to-air missiles for the U.S. Air Force A-10
aircraft, the A-4 modernization programs for the Royal Air Force of New Zealand
and certain aircraft flown by the Greek Air Force. This technology has also
been applied by the Company to a Sidewinder control system for the F-5 aircraft
and a $12.2 million U.S. Air Force contract for delivery to the Taiwanese Air
Force.
Base Ten has funded research and development of technology used for the
control of air-to-air and air-to-ground missiles such as Sidearm, Stinger and
Mistral and has provided a missile control system for the Stinger missile for
experimental use aboard the Apache helicopter. The Company's Government
Technology Division is
4
<PAGE>
currently engaged in marketing activities to encourage sales of these products
but cannot be assured of any future business.
Base Ten has been selected by the Northrop Corporation to be a member of
its F-5 upgrade program. Northrop is pursuing current F-5 fleet owners to
upgrade and improve their equipment. The Company expects to participate in any
resulting sales with its Sidewinder control system as well as other portions of
the weapons control hardware. In the absence of production orders for these
products or other military products, Base Ten could have difficulty meeting its
revenue goals for fiscal 1996.
The Company also manufactures defense products to specifications for prime
contractors. Base Ten has supplied McDonnell Douglas Helicopter Co. as a
contract manufacturer of electronic systems used aboard the Apache helicopter
and more recently has become a contract manufacturer for SPD Technologies, Inc.,
a circuit breaker manufacturer, and agencies of the U.S. government.
SECURE COMMUNICATIONS PRODUCTS
Base Ten has engaged since 1989 in the development and sale of products for
secure communications systems. The Company's initial product in this field was
a telecommunications interface known as a TCIA for the transmission of encrypted
data over a conventional T1 telephone line. The interface was endorsed by the
National Security Agency in 1991 but has been restricted to government users.
Base Ten has also developed proprietary encryption devices using surface mount
technology, endorsed by the National Security Agency in 1992 as its sole
authorized supplier, and has supplied related test equipment on a contract
manufacturing basis. Base Ten won these test equipment contracts in competitive
bids and is now recognized as an independent source for these products.
In 1991 the Company won a competitive bid to build Bus Interface Units for
the Navy's communication system using the Navy's design. Base Ten subsequently
created a proprietary device, known as the Bus Interface Card (BIC) to
substitute for the Bus Interface Unit, and has since sold over 7,000 of these
devices. The Company anticipates further contracts for this product over the
next several years. To extend the sales life of a BIC, the Company developed a
proprietary device known as the Sychrononous Line Interface Card (SLIC). The
SLIC is suitable for laptop computers and performs the same functions as the
BIC. The Company has taken small orders for this device and believes that it
will eventually replace the BIC as the device of choice.
While the type of engineering and manufacturing required to design and
produce secure communications devices is compatible with the company's
capabilities and experience in safety critical products, its sales to date have
been limited to government users. Base Ten believes this market is gaining
interest in commerce and industry but cannot predict either the timing of
clearance for sales of its secure communications products to nongovernment
users or, if cleared, the potential for any commercial sales.
MANUFACTURING
The Company's manufacturing operations primarily involve the assembly and
testing of final products from components and subassemblies purchased from other
manufacturers. Product assembly is conducted at the Company's plant in Trenton,
New Jersey.
Base Ten purchases a variety of components such as transistors, resistors,
integrated circuits, capacitors, connectors and diodes for use in the
manufacture of its products. The Company has more than one source of supply for
most of its purchased components. Where only one source exists, Base Ten
attempts to maintain an inventory of material to cover foreseeable production
needs. Should expedited delivery or significantly increased rates of production
be required and the single source unable to support inventory requirements, the
Company could experience production delays and increased costs.
The Company has historically received advance and progress payments from
time to time in order to establish inventory levels on long lead items required
for making timely delivery of certain products to its customers. Base Ten
expects this practice to continue for a decreasing percentage of its products,
requiring the Company to finance more of its backlog internally. Base Ten
maintains inventory of both components and finished products that it considers
necessary to satisfy both booked orders and expected repairs. The Company's
defense products are not returnable except for repair. Normal payment terms are
net 30 days.
5
<PAGE>
In its contract manufacturing operations, Base Ten purchases the necessary
components and materials and provides electronic assembly, testing and quality
assurance services to prime defense contractors to build and test equipment
designed by those contractors. In addition, the Company offers supporting
engineering services to develop a prime contractor's design into a producible
device and to solve technical and manufacturing problems. The contracts for
these programs can be canceled on short notice at the customer's convenience and
are subject to government budget considerations.
TRADEMARKS AND PATENTS
Base Ten has pending federal trademark applications for registration of
PRENVAL-TM-, MED-DOS-TM- and PHARMASYST-TM-. In addition, a basic patent for
the Company's MED-DOS technology was granted in 1994, with two allowances
expanding the patent received in 1995. Base Ten has also received allowances on
a patent for a portable memory device and a patent directed to the method of
assessing medical risk. Additional patent applications have been filed covering
innovative work on imaging products, pharmaceutical recordkeeping systems and
certain aspects of the Company's safety critical technology. Base Ten believes
that its pending patent applications have substantial merit but cannot predict
their outcome or potential effect on its operations.
Base Ten has funded a patent application covering technology for the
detection of various mental diseases in exchange for the right to negotiate with
the owners of the application for its commercial development. The Company
cannot predict if or when the patent will be granted and has only until February
1996 to make a firm offer for the prospective commercialization. As of the date
of this Report, the Company has not determined whether to commit to this
development.
Base Ten has no proprietary rights for its defense products other than a
patent granted in 1995 on an application filed by its Government Technology
Division covering the fuzing of rockets.
REGULATION
NONDEFENSE PRODUCTS. Some of the Company's medical software products
require premarket approval from the FDA before they can be marketed in the
United States and are subject to regulatory requirements of other nations,
principally the EEC. The Company's primary medical software product, the batch
processing control system marketed as PHARMASYST-TM-, does not require
regulatory approval at this time.
Base Ten believes it is capable of complying with FDA and other regulatory
design requirements but may not be able or not wish to fund required clinical
studies in certain cases. In those cases, development may be postponed until
the Company can establish relationships with other parties prepared to perform
the required trials. On new medical software products, Base Ten seeks to
determine the extent of required clinical trials prior to beginning development.
DEFENSE PRODUCTS. Most of the Company's foreign sales involve defense
related products that are subject to export control through the Department of
State's Office of Munitions Control under the International Traffic in Arms
Regulations (ITAR) adopted under the Arms Export Control Act. All articles and
services listed on the United States Munitions list, which may be amended from
time to time, fall under these regulations, are primarily military in character.
In order to export products or services subject to these regulations, the
Company must first acquire licenses from the Department of State for each
individual contract it wishes to fulfill. State Department policies, as
supplemented or modified by the Department of Defense or other applicable
government agencies, identify both products that cannot be exported and
countries to which export is prohibited or limited, and the Company must in all
cases comply with these policies. ITAR also imposes certain restraints in
foreign customer contracts and defense product development. Since Base Ten
intends to continue its pursuit of foreign military sales as a source of
revenue, ongoing compliance with ITAR is necessary.
Should government policy dictate that any of the Company's products are of
a sensitive technological character in which the best interests of the United
States will be served by prohibiting their export, Base Ten could suffer a
serious and immediate loss of business. The Company's principal foreign markets
for defense related products are located in the NATO countries and other nations
friendly to the United States. To date, the United States government has not
denied requests by Base Ten for licenses to export any of its products or
technical data to these countries except in instances where all United States
manufacturers of similar products would be equally
6
<PAGE>
denied.
The Company's United States military contracts are subject to pricing
restrictions and to audit and renegotiation by the government. After being
selected as the successful bidder for a government contract, prices for most
products and systems developed for domestic defense programs are subject to fact
finding, with negotiated profits limited to approximately 10% of cost, all of
which are not recognized by the U.S. Department of Defense. The Company has
undergone routine government audits of its defense contracts from time to time.
These audits have upheld the Company's pricing in all cases.
BACKLOG
Backlog at October 31, 1995 was approximately $6.6 million, of which $6.1
million or 92% is scheduled for delivery throughout fiscal 1996. Approximately
$4.6 million or 69% of the backlog at the end of fiscal 1995 was weapons
related. The remainder was derived 2% from government contracts for secure
communications equipment and 29% from batch processing and medical software,
principally PHARMASYST-TM- bookings. While Base Ten is attempting to develop
commercial markets for its nondefense products, it is just beginning to develop
meaningful revenues from those operations. In the absence of continued market
penetration for these new products, the Company's sales will be primarily
dependent on defense related markets.
Substantially all of the Company's orders for defense related products may
be canceled at any time at the convenience of the customer, subject to various
payment obligations for prior shipments and materials on hand at the time of
cancellation. In the event of any default in the Company's contract
obligations, orders may be canceled at no cost. The current defense budget
reductions represent a more restrictive procurement climate than previously
experienced, and any substantial cancellations could have an immediate adverse
effect on the Company's business.
For PHARMASYST-TM- orders, the Company has offered certain customers the
right to cancel at no cost early in the contract cycle if the parties and the
customer do not agree on the applicable specifications for the installed
PHARMASYST-TM- software. Base Ten has not experienced any cancellations to date
under this policy.
COMPETITION
The Company experiences intense competition in virtually all areas of its
business, including its newer concentrations in the fields of batch processing
control, medical screening and image archiving software. The areas in which the
Company operates are characterized by rapid technological change, with many
competitors having far greater resources and more established reputations than
the Company. While Base Ten believes that its products incorporate advanced
technology, competing firms could introduce comparable products with more
advanced features. Base Ten believes the potential markets for manufacturing
execution systems and medical software are so large that more substantial and
experienced firms may seek to compete, possibly depriving the Company of certain
opportunities. In addition, reductions in military spending has accelerated
competitive pressures.
Base Ten emphasizes engineering features, technical competence, performance
and reliability in the development and sales of its products and high quality
workmanship in its contract manufacturing operations. The Company competes
primarily on the basis of those engineering features while also seeking to
provide prompt and responsive contract performance and delivery at reasonable
prices.
RESEARCH AND DEVELOPMENT
The Company's research and development (R&D) costs during fiscal 1995, 1994
and 1993 were $.9 million, $.9 million and $.4 million, respectively. The level
of R&D in fiscal 1995 reflects the Company's capitalization of medical software
costs aggregating $2.3 million and the exclusion of substantial management and
marketing resources covered under selling, general and administrative costs.
Base Ten believes its expenditures for R&D will increase substantially in the
future, both absolutely and as a percentage of revenues.
EMPLOYEES
As a result of its cost reduction program, Base Ten's labor force in the
United States has changed since 1990 from 284 persons, including 19 engineers
and designers, to a current total work force of 168 persons, including 33
engineers and designers, plus contract labor. The Company's subsidiary in
Ireland employs two software
7
<PAGE>
engineers, and its subsidiary in England employs four software engineers. Base
Ten plans to add to its technical staff as orders are generated in its Medical
Technology Division. None of the Company's employees are covered by collective
bargaining agreements. Base Ten has never experienced any labor disruptions or
work stoppages and considers its employee relations to be good.
SECURITY CLEARANCE
The Company relies on the continuance of its security clearances from
agencies of the United States government and from NATO for its defense products.
Loss of these clearances would have an immediate and adverse effect on the
Company's business. Base Ten has never experienced any material deficiencies in
the manner and method of complying with prescribed security regulations and
expects to continue as an approved facility.
BUSINESS SEGMENTS AND FOREIGN OPERATIONS
Information on the Company's business segments and operations in different
geographic areas is provided in Note G to the Consolidated Financial Statements
included elsewhere in this Report.
ITEM 2. PROPERTIES
Base Ten leases offices and manufacturing space in three countries. The
principal United States and international facilities are as follows:
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SQUARE FOOTAGE
OCCUPIED BY
LOCATION TYPE OF FACILITY EXPIRATION THE COMPANY
---------------------------------------------------------------------------
Trenton, New Jersey Corporate headquarters, October 2009 62,000
Including engineering,
manufacturing and
support facilities
Farnborough, England Administrative offices March 2003 1,000
Dublin, Ireland Administrative offices Month to month 390
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Management believes that the Company's facilities are adequate for its
operations and are maintained in good condition. The Company's facility in
Trenton is subject to a lease described in Note H to the Company's Financial
Statements included elsewhere in this Report.
ITEM 3. LEGAL PROCEEDINGS
No material legal proceedings are pending by or against the Company and, to
the knowledge of Base Ten, none are contemplated against the Company by
governmental authorities.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
No matters were submitted to a vote of the Company's shareholders during
the fourth quarter of fiscal 1995.
8
<PAGE>
PART II
ITEM 5. MARKET FOR THE COMPANY'S COMMON STOCK AND RELATED SHAREHOLDER MATTERS
The Company's Class A Common Stock is listed on the Nasdaq National Market
under the trading symbol BASEA, and the Company's Class B Common Stock is
traded in the Nasdaq Over the Counter Market and quoted on its Supplemental List
under the trading symbol BASEB.
The following table sets forth the high and low sale prices of the
Company's Class A Common Stock and Class B Common Stock as reported by Nasdaq
for the periods indicated:
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
CLASS A COMMON STOCK CLASS B COMMON STOCK
SALE PRICES SALE PRICE
-------------------- --------------------
HIGH LOW HIGH LOW
------- ------ ------- -------
FISCAL 1995:
<S> <C> <C> <C> <C>
First quarter. . . . . . $ 8 1/4 $6 1/4 $ 8 $ 6 5/8
Second quarter . . . . . 9 $6 3/4 $ 9 1/8 $ 7 1/2
Third quarter. . . . . . 10 1/8 6 3/4 10 3/4 7
Fourth quarter . . . . . 11 5/8 9 1/8 12 3/8 10 1/8
FISCAL 1994:
First quarter. . . . . . $9 3/4 $7 3/4 $9 1/2 $7 3/4
Second quarter . . . . . 9 1/4 7 1/8 9 1/8 7 1/4
Third quarter. . . . . . 9 1/2 6 5/8 9 1/4 6 5/8
Fourth quarter . . . . . 9 5/8 7 3/8 9 1/2 7 1/2
</TABLE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
As of December 31, 1995, there were approximately 728 record holders of
Class A Common Stock and 174 record holders of Class B Common Stock.
Base Ten has not paid cash dividends on its Common Stock since 1985. The
present policy of the Board of Directors is to retain any future earnings to
provide for the Company's growth.
9
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA
The following table presents selected financial data for Base Ten and its
subsidiaries. The financial data for the fiscal years ended October 31, 1993
through October 31, 1995 have been derived from the Company's audited
Consolidated Financial Statements included elsewhere in this Report and should
be read in conjunction with those Consolidated Financial Statements and related
Notes.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
BASE TEN SYSTEMS, INC. AND SUBSIDIARIES
(IN THOUSANDS EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, 1995 1994 1993 1992 1991
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
SUMMARY OF OPERATIONS:
Revenues $ 18,307 $ 19,282 $ 22,262 $ 19,068 $ 27,059
Earnings (loss) from continuing
operations before income taxes
and extraordinary item(1)(2) $ (1,349) $ 59 $ 1,465 $ 695 $(14,442)
Income taxes (benefit) $ (474) $ 24 $ 507 $ 198 $ (1,600)
Net earnings (loss) from
continuing operations before
extraordinary item $ (875) $ 35 $ 958 $ 497 $(12,842)
Extraordinary Item:
Income tax/benefit from
utilization of loss carryforward $ -- $ -- $ -- $ 198 $ --
Net earnings (loss) $ (875) $ 35 $ 958 $ 695 $ 12,842)
- ------------------------------------------------------------------------------------------------------------------------------
Net earnings (loss) per share $ (.13) $ .03 $ .17 $ .19 $ (3.65)
- ------------------------------------------------------------------------------------------------------------------------------
SUMMARY BALANCE SHEET
- ------------------------------------------------------------------------------------------------------------------------------
<CAPTION>
YEAR ENDED OCTOBER 31, 1995 1994 1993 1992 1991
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
SUMMARY OF OPERATIONS:
Working capital $ 14,420 $ 5,860 $ 6,365 $ 1,858 $ 2,602
Total assets $ 28,005 $ 17,609 $ 17,255 $ 13,054 $ 20,835
Long term debt, net of
current maturities (3) $ 3,525 $ 3,601 $ 3,212 $ 4,675 $ 6,000
Shareholders' equity $ 20,261 $ 9,431 $ 7,957 $ 1,974 $ 1,176
- ------------------------------------------------------------------------------------------------------------------------------
</TABLE>
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
(1) Included in 1991 financial data are restructuring costs of $5.4
million and a loss on marketable securities of $2.1 million.
(2) Included in 1992 financial data is a reversal of $.5 million of a
prior provision and a gain of $.4 million on previously written-off
marketable securities.
(3) Included in 1995 and 1994 financial data is a long term capital lease.
10
<PAGE>
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
Base Ten has historically specialized in the design and manufacture of
electronic systems employing safety critical software for defense markets, both
nationally and internationally. The Company also manufactures defense products
to specifications for prime government contractors and designs and builds
proprietary electronic systems for use in secure communications applications by
various U.S. government agencies. Specialization in these extreme reliability
defense products has enabled the Company to develop expertise in the field of
safety critical technology dedicated to the prevention of performance errors.
During the last several years, Base Ten has redirected its resources and
streamlined its operations in response to the worldwide reduction in defense
spending. Since 1990, Base Ten has sold or discontinued various foreign
operations, downsized part of its domestic operations and emphasized new
commercial product development programs with a view to balancing its business
activities. These programs have manufacturing execution, medical screening and
image archiving products with significant potential markets. Each of these
products rely on the same safety critical techniques developed in the Company's
established businesses. Although revenues from these operations have yet to
offset the decline in defense revenues, the Company has augmented its technical
and sales staff to support increased development and marketing operations in
both commercial and government markets.
RECENT DEVELOPMENTS
DEFENSE OPERATIONS. The Company's primary revenue source during the last
three years has been defense related programs with the United States military
and other agencies or contractors. These programs accounted for $7.4 million
or 40.4% of revenues in fiscal 1995, $5.4 million or 28% of revenues in 1994 and
$15.1 million or 67.8% of revenues, in 1993. The largest program was a
Sidewinder control system comprised of flight line, intermediate level and depot
test equipment for the F-5 aircraft under a $12.1 million contract completed in
1994 for delivery to the Taiwanese Air Force. The Company's domestic defense
related programs have also included contract manufacturing for various prime
contractors.
During the last three years, the sale of weapons control systems for the
Tornado program has also remained a major source of revenues. Base Ten's
participation in this program has included the preparation of software upgrades
and new product development to enhance the aircraft's mission capabilities as
well as SMS production orders. These operations accounted for $6.6 million or
36% of revenues in 1995, $7.0 million or 36% of revenues in 1994 and $3.8
million or 17% of revenues in 1993. Late in 1995, Base Ten received full
funding on a Tornado production contract, resulting in acceleration of the
manufacturing schedule, with most of the work expected to be completed in 1996.
In the first quarter of fiscal 1996, the Company received initial funding for
a new software program for the Tornado program under a contract valued at $1.8
million and scheduled to be completed in early 1997.
Despite profit margins limited by strict government procedures and intense
competition, the Company's defense related operations have provided a relatively
stable revenue base, while enabling Base Ten to maintain its position as a
seasoned provider of safety critical control systems developed for high
reliability under stringent performance standards. To enhance this position,
Base Ten has invested its own funds from time to time in product development for
the domestic defense market, including recent investments in the development of
a new weapons control system for helicopters and a new gun control unit for a
popular chain gun. While these efforts have not always resulted in sales, Base
Ten aggressively pursues opportunities in this market and will continue to seek
participation in defense programs that utilize its established technologies and
skills. Current activities in this area include extensive quotations to
international customers under the ITAR rules.
In 1995, Base Ten supplied its upgraded computer interface known as the BIC
to the U.S. Navy. The Company expects to receive additional orders for BIC
cards from this customer in 1996. In addition to its telecommunications
interface products, Base Ten has developed proprietary encryption devices
endorsed by the National Security Agency. While sales of the Company's secure
communications products have been limited to government users. Base Ten
believes this technology may present commercial opportunities that it would
expect to pursue if they arise.
NONDEFENSE OPERATIONS. During the last three years, the Company advanced
its business plan for redeploying resources to commercial applications by
concentrating development efforts on products requiring the
11
<PAGE>
application of its electronic, software and systems engineering capabilities in
safety critical, highly regulated environments. The Company's commercial
development efforts through its Medical Technology Division have been focused on
manufacturing execution, medical screening and image processing software as well
as secure communications products. While these efforts have been internally
funded and could be adversely affected by delays in the development cycle,
competition and changing technology, sales of these proprietary products could
be expected to provide more favorable profit margins than the Company's defense
business.
In 1995, the Company's Medical Technology Division generated $2.2 million
or 12% of total revenues, primarily from sales of the Company's PRENATA-TM-
medical screening software through Johnson & Johnson and the manufacturing
execution system marketed as PHARMASYST-TM-. As of the date of this Report,
Base Ten has received bookings and notifications of its selection by
pharmaceutical companies expected to result in PHARMASYST-TM- installations in
over 30 sites throughout the world, including sales to Miles Pharmaceuticals,
Abbott Hospital Products Division, Pfizer International Products Group,
Minnesota Mining and Manufacturing, Nycomed, Berlex and others. In addition,
given the flexibility and broad market applicability of this product, marketing
efforts during 1995 were expanded to other regulated industries, with initial
PHARMASYST-TM- sales made to Frito Lay.
The Company has significantly increased its technical staff and facilities
to accommodate anticipated growth in this field and is actively pursuing
additional PHARMASYST-TM- sales to the pharmaceutical and other regulated
industries, both domestically and abroad. In view of the initial success and
market potential of its PHARMASYST-TM- system, Base Ten intends to continue
concentrating resources in the refinement and marketing of this product. The
shift in resources to exploit these opportunities contributed to the Company's
net loss in 1995 and can be expected to have an adverse impact on its financial
results until PHARMASYST-TM- sales increase.
During 1995, Base Ten also concentrated on the introduction of its uPACS
archiving system for ultrasound images. Although this product line has not yet
generated meaningful revenues and faces rigorous competition on both price and
features, the Company is endeavoring to overcome these obstacles with advances
in the design, including a networking feature to reduce the cost of the system
relative to the number of ultrasound scanners being serviced. Selling efforts
are underway in Europe through several distributors, and alliances are being
sought with OEM manufacturers and important users of ultrasound systems in the
EEC. In addition, Base Ten plans to file a 510K premarket notification
application in early 1996 to secure FDA clearance for uPACS sales in the United
States. While the Company believes its uPACS product fills an important market
need and could generate significant revenues over the next decade, opportunities
in this field could be eroded by competition, potentially requiring Base Ten to
discontinue further development and expense the capitalized costs incurred to
date.
After several years of approval procedures, Base Ten received FDA clearance
for its PRENVAL-TM- 1 medical screening software during 1995 on the basis of its
510(K) premarket notification, positioning the Company as a supplier of safety
critical medical devices. Although the basic software used in PRENVAL-TM- 1 can
be applied to other CATI programs, the Company has temporarily delayed applying
further resources to this product line to exploit the greater near term
potential of its PHARMASYST-TM- systems and potentially benefit from current
discussions and hearings by the FDA on its medical software regulations, any
simplification of which could enable the Company to complete future medical
software products at lower costs.
During 1995, Base Ten recognized revenues under its licensing agreement
with J&J, covering the introduction of the Company's more complex PRENATA-TM-
medical screening software into the European market. The agreement is expected
to generate royalties for the remainder of the current term ending in 1999.
Under the agreement, the Company is entitled to certain minimum royalties but
could receive substantially greater revenues if the product is successfully
marketed by J&J. In addition, despite regulatory obstacles, the Company intends
to pursue domestic sales of PRENATA-TM- or a similar program if a suitable
marketing partner willing to absorb the cost of clinical trials can be found.
Unlike many defense programs in which the Company participates, current
development activities for nondefense products are being funded by Base Ten.
Although most of the development costs for these programs is capitalized, the
amortization of the capitalized development expenses along with substantial
growth in sales and marketing costs will continue to impact the Company's
financial results. Moreover, limited financial resources could impair the
Company's ability to successfully complete the development and marketing of
resulting products.
12
<PAGE>
RESULTS OF OPERATIONS
SEASONALITY. The Company's revenues and operating results are subject to
quarterly fluctuations due primarily to the timing of contract stage completions
and product deliveries. These factors are characteristic of Base Ten's business
environment and can affect quarterly performance materially without necessarily
reflecting results for the full year or long term profitability. In the fourth
quarter of 1995, the Company experienced delays in order writing for its defense
products, resulting in reduced shipment schedules for the first fiscal quarter
of 1996. In addition, despite steadily increasing PHARMASYST-TM- orders, the
percentage of completion method used by Base Ten in accounting for these orders
results in its recognition of revenues from PHARMASYST-TM- sales primarily
toward the beginning of the installation schedule. Although these factors plus
higher marketing expenses are expected to result in a loss for the first quarter
of fiscal 1996, the Company anticipates a return to profitability later in
1996 based on anticipated shipment schedules for the balance of the year.
COST REDUCTION PLAN. The nature of the Company's business requires it to
maintain significant engineering and management resources to fulfill existing
contracts and take advantage of business opportunities as they arise, with
external sources generally utilized on a short term basis to satisfy peak
overloads. To reflect current conditions, wages were increased at the beginning
of 1995 after remaining generally unchanged for two years. The higher labor
costs do not necessarily result in comparable price increases for the Company's
products due to competitive forces.
In order to improve financial performance pending anticipated revenue gains
from the Company's Medical Technology Division in 1996, Base Ten implemented a
cost reduction plan in 1995. Under the plan, each officer of the Company and
its divisions worked for the minimum wage during a three month period beginning
May 15, 1995. Each of these employees other than the Chairman received three
year loans equal to their relinquished salary with interest at 6.5% annually.
The Chairman and the Presidents of the Company's two divisions continued to work
for the minimum wage for the balance of the fiscal year, and the two Presidents
received three year loans for the additional relinquished salary. All of the
employee loans will be repayable either in cash or as an offset against future
compensation. Subject to meeting its performance goals, the Company will adjust
1996 compensation with an 8.5% increase in salary levels and an incentive plan
based on earnings performance.
The cost reduction plan also includes a decrease in manufacturing staff, a
suspension of various consulting agreements and other cost saving measures. In
addition, as a means of optimizing the use of Base Ten's manufacturing facility,
certain defense products with an established market expected to result in 1996
sales were built to inventory during 1995.
FISCAL 1995 COMPARED TO FISCAL 1994. Revenues for the twelve months ended
October 31, 1995 were $18.3 million compared to $19.3 million in 1994, a
decrease of 5.1%. The decrease in revenues reflects reduced defense budgets in
both the United States and Western Europe, the Company's two largest markets.
Approximately 85% of fiscal 1995 revenues were generated from various contracts
for weapons control software, development of new software for the Tornado
program, some Tornado production work and contract manufacturing. The balance
of Base Ten's revenues during the year was generated from PHARMASYST-TM- sales
and revenues from the Company's license agreement with J&J for PRENATA-TM-
medical screening software.
Cost of sales as a percent of revenues in fiscal 1995 declined to 64.5%
from 67.4% in 1994. The improved performance reflects a shift in product mix to
include a higher percentage of software and engineering content, with a
corresponding decrease in material costs. Although the direct labor content of
sales by the Medical Technology Division increased in 1995, higher margins were
maintained through capitalization of the associated software development costs.
R&D costs charged as expense in fiscal 1995 decreased to $863,000 or 4.7%
of revenues from $887,000 or 4.6% of 1994 revenues. R&D costs do not include
software development costs of $2.3 million capitalized in 1995 compared to $1.5
million in 1994. Most of the capitalized costs incurred in 1995 were
attributable to the development of PHARMASYST-TM- software by the Medical
Technology Division. Extensive efforts to accelerate the marketability of
PHARMASYST-TM- as well as PRENVAL-TM- medical screening software and the uPACS
archiving system for ultrasound images were recorded as selling, general and
administrative expenses rather than R&D costs.
13
<PAGE>
Selling, general and administrative expenses increased to $6.4 million in
fiscal 1995 or 35.1% of revenues compared to $5.1 million or 26.6% of revenues
in fiscal 1994. The increase in selling, general and administrative expenses
reflects expanded marketing activities primarily for the Company's nondefense
products. Selling, general and administrative expenses include direct labor
costs of $3.3 million in fiscal 1995 compared with $2.5 million in 1994.
Interest expense was $0.6 million in 1995 and $0.2 million in 1994. All of
the 1995 interest expense represents capitalized lease costs incurred under a
sale and lease back transaction involving the sale of the Company's facility in
Trenton, New Jersey and repayment of the outstanding mortgage loan at the end of
1994. The transaction resulted in total long term lease obligations aggregating
$3.6 million.
After accounting for an income tax benefit of $474,000, Base Ten incurred a
net loss of $875,000 or $.13 per share in 1995 compared to net earnings of
$35,000 or $.03 per share after income taxes of $24,000 in 1994. The loss per
share in 1995 was based on 6.9 million weighted average shares compared to 7.6
million fully diluted shares in 1994. The dilutive effect of outstanding
options, rights and warrants was determined using the weighted average shares
outstanding for the 1995 calculation and the modified treasury stock method for
1994.
FISCAL 1994 COMPARED TO FISCAL 1993. Revenues for the twelve months ended
October 31, 1994 decreased 13.4% to $19.3 million compared with $22.3 million
in 1993. The decrease in revenues reflects reduced defense budgets in both the
United States and Western Europe. Fiscal 1994 revenues were generated from
various contracts for weapons control software, development of new hardware for
the Tornado program, some Tornado production work, production of Bus Interface
Units for the U.S. Navy and contract manufacturing.
Cost of sales as a percent of revenues in fiscal 1994 was 67.4% compared to
67.2% in 1993. Despite the reduced volume reflecting a smaller base over which
to spread certain fixed overhead costs and additional costs from two contract
overruns, consistency in cost of sales was achieved by a reduction of
approximately $300,000 in manufacturing expenses.
R&D costs shown as expenses in fiscal 1994 increased to $887,000 from
$403,000 in 1993 due to increased development costs for certain defense related
and secure communication products. R&D costs for PHARMASYST-TM-, PRENVAL-TM-
and ultrasound imaging products were capitalized at $1.5 million for 1994, with
an aggregate capitalized cost since the start of development of $2.1 million
through the end of 1994. Extensive efforts to accelerate the marketability of
PHARMASYST-TM- and PRENVAL-TM- software products were recorded as selling,
general and administrative expenses rather than R&D costs.
Selling, general and administrative expenses were $5.1 million in fiscal
1994 or 26.6% of revenues compared to $5.1 million or 23.1% of revenues in
fiscal 1993. The increase in selling, general and administrative expenses as a
percentage of revenues primarily reflects expanded marketing activities relative
to the reduced revenue base. Selling, general and administrative expenses
include direct labor costs of $2.5 million in fiscal 1994 compared with $2.6
million in 1993.
Interest expense declined from $0.3 million in 1993 to $0.2 million in 1994
as a result of reduced borrowings. No borrowings were made under the Company's
$1 million line of credit in 1994. Later in the year, long term debt was
eliminated through the sale of the Company's facility in Trenton, New Jersey and
repayment of the outstanding mortgage loan, although the transaction resulted in
long term lease obligations aggregating $3.6 million.
Net earnings for fiscal 1994 were $35,000 or $.03 per share on 7.6 million
fully diluted shares compared with $958,000 or $.17 per share on 7.1 million
fully diluted shares in the prior fiscal year, reflecting reduced revenues
without a corresponding reduction in R&D and selling, general and administrative
costs. Management's decision to maintain a high level of research and
development as well as marketing activities was taken to provide the basis for
future revenue growth.
14
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
LIQUIDITY. Significant liquidity factors are as follows:
<TABLE>
<CAPTION>
---------------------------------------------------------------------------
OCTOBER 31, 1995 OCTOBER 31, 1994
---------------- ----------------
<S> <C> <C>
Working capital $14,420,000 $5,860,000
Current ratio (1) 4.8 to 1 2.5 to 1
Debt to equity ratio (2) .38 to 1 .87 to 1
Unused line of credit N/A $1,000,000
---------------------------------------------------------------------------
</TABLE>
(1) The ratio of current assets to current liabilities.
(2) The ratio of total liabilities to shareholders' equity.
These ratios all improved during 1995 due principally to funds raised from
the exercise of outstanding Series B Rights and Class A Common Purchase Warrants
prior to their expiration. The Company received net proceeds in the
transactions aggregating $11.1 million. A portion of the proceeds was used to
fund an increase of $2.1 million in accounts receivable and an increase of $2.1
million in other assets principally comprised of capitalized software
development costs. Cash remaining at October 31, 1995 totaled $7.2 million, an
increase of $5.4 million over the prior year.
CAPITAL RESOURCES. At the end of fiscal 1994, the Company maintained a
$1.0 million credit facility with The Bank of New York. In view of its cash
position, Base Ten let the facility expire in January 1995.
In November 1994, Base Ten issued 816,709 shares of its Class A Common
Stock upon the exercise of substantially all the Company's expiring Series B
Rights at an exercise price of $6.00 per share. Net proceeds from the exercise
of the Series B Rights aggregated approximately $4.2 million. In April and May,
1995, the Company issued approximately 1.2 million shares of its Class A Common
Stock upon the exercise of substantially all the expiring Class A Common
Purchase Warrants at an exercise price of $6.00 per share. Net proceeds from
the exercise of the Warrants totaled approximately $6.9 million.
The Company believes that its working capital and funds generated from
operations will be sufficient to support its operations and planned development
activities. Accordingly, Base Ten does not anticipate incurring any long term
borrowings to support its operations for the foreseeable future.
INFLATION. A significant portion of the Company's inventory is funded by
its customers and committed to specific orders. As a result, the effects of
inflation are not significant to Base Ten's operations.
15
<PAGE>
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO FINANCIAL STATEMENTS
PAGE
----
Independent Auditors' Report . . . . . . . . . . . . . . . . . . . . . . 19
Consolidated Balance Sheets - October 31, 1995 and 1994. . . . . . . . . 20
Consolidated Statements of Operations - Years ended October 31, 1995,
1994 and 1993 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Consolidated Statements of Shareholders' Equity - Years ended
October 31, 1995, 1994 and 1993 . . . . . . . . . . . . . . . . . . . . 22
Consolidated Statements of Cash Flows - Years ended October 31, 1995,
1994 and 1993 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . 24
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
Not Applicable
16
<PAGE>
PART III
ITEM 10. EXECUTIVE OFFICERS OF THE COMPANY
The executive officers of the Company and other members of senior management are
as follows:
- --------------------------------------------------------------------------------
NAME AGE OFFICES HELD WITH BASE TEN PERIOD SERVED
- --------------------------------------------------------------------------------
Myles M. Kranzler 67 Chairman of the Board, President 1966 to present
and Chief Executive Officer
James A. Eby 65 Senior Vice President-Engineering 1982 to present
Vice President-Engineering 1974 to 1982
Edward J. Klinsport 48 President-Government Technology 1994 to present
Div.
Executive Vice President 1992 to present
Chief Financial Officer 1978 to present
Group Vice President 1985 to 1992
Alan J. Eisenberg 54 President-Medical Technology Div. 1994 to present
Vice President 1983 to present
Richard J. Farrelly 64 Vice President 1992 to present
Frank W. Newdeck 50 Vice President 1991 to present
Richard G. Kandrac 54 Vice President 1983 to present
- --------------------------------------------------------------------------------
A summary of the business experience and background of the Company's
officers and directors is set forth below.
MR. KRANZLER has been the Chairman of the Board, President and Chief
Executive Officer of Base Ten since the Company's inception in 1966. He has
also served as a director of the Company since its inception.
MR. EBY has been the Chief Engineer of the Company since February 1966. He
became a Vice President in 1974 and a Senior Vice President in 1982. He has
also served as a director of the Company since 1966.
MR. KLINSPORT has been the Chief Financial Officer of Base Ten since 1978.
He has served as Executive Vice President of the Company since October 1992 and
was elected President of the Government Technology Division in November 1994.
He has also served as a director of the Company since 1985.
MR. EISENBERG has been employed by Base Ten since 1980. He has been a Vice
President of the Company since 1983 and is responsible for its software
activities. Mr. Eisenberg was elected President of the Medical Technology
Division in November 1994. He has also served as a director of the Company
since 1992.
MR. FARRELLY has been employed by the Company since June 1988 and became a
Vice President, responsible for corporate development, in June 1992. Mr.
Farrelly was formerly General Manager of the Reentry Systems Division of General
Electric Aerospace Company.
MR. KANDRAC has been employed by the Company since 1969 and became a Vice
President in 1983, responsible for manufacturing and purchasing.
MR. NEWDECK has been employed by the Company since 1990 and became a Vice
President in 1991, with responsibilities in the Government Technology Division.
Prior to joining the Company, Mr. Newdeck was General Manager of the Network and
Information Security Division of Unisys Corporation.
The balance of Part III of this Report is incorporated by reference to the
Company's definitive Proxy Statement to be filed before February 28, 1996 for
its forthcoming Annual Meeting of Shareholders.
17
<PAGE>
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENTS AND REPORTS ON FORM 8-K
(a) FINANCIAL STATEMENTS AND SCHEDULES:
1. FINANCIAL STATEMENTS: The Financial Statements listed in the Index
under Item 8 are included in this Report.
2. SCHEDULES: The schedules for which provision is made in Regulation S-X
of the Securities and Exchange Commission are not required under the
related instructions or are inapplicable and therefore have been
omitted.
3. EXHIBITS: See the Exhibit Index on pages 35 through 37 of this
Report.
(b) REPORTS ON FORM 8-K: The Company did not file any Current Reports on
Form 8-K during the fourth quarter of fiscal 1995.
18
<PAGE>
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Shareholders
Base Ten Systems, Inc.
Trenton, New Jersey 08619
We have audited the consolidated balance sheets of Base Ten Systems, Inc. and
subsidiaries as of October 31, 1995 and 1994, and the related consolidated
statements of operations, shareholders' equity and cash flows for each of the
three years in the period ended October 31, 1995. These financial statements
are the responsibility of the Company's management. Our responsibility is to
express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the financial position of Base Ten Systems,
Inc. and subsidiaries as of October 31, 1995 and 1994, and the results of their
operations and their cash flows for each of the three years in the period ended
October 31, 1995 in conformity with generally accepted accounting principles.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
December 15, 1995
19
<PAGE>
BASE TEN SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
- --------------------------------------------------------------------------------
OCTOBER 31, 1995 1994
- --------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
CURRENT ASSETS:
Cash $ 7,221,000 $ 1,868,000
Accounts receivable (including unbilled
receivables of $4,421,000 in 1995 and
$2,006,000 in 1994) 7,184,000 5,068,000
Inventories 3,151,000 2,411,000
Other current assets 644,000 417,000
- --------------------------------------------------------------------------------
TOTAL CURRENT ASSETS 18,200,000 9,764,000
PROPERTY, PLANT AND EQUIPMENT 4,480,000 4,582,000
OTHER ASSETS 5,325,000 3,263,000
- --------------------------------------------------------------------------------
TOTAL ASSETS $28,005,000 $17,609,000
- --------------------------------------------------------------------------------
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses $ 2,700,000 $ 2,541,000
Income taxes payable 1,038,000 1,363,000
Current portion of Capital Lease Obligation 42,000 --
- --------------------------------------------------------------------------------
TOTAL CURRENT LIABILITIES 3,780,000 3,904,000
- --------------------------------------------------------------------------------
LONG-TERM LIABILITIES:
Deferred Income Taxes 83,000 243,000
Deferred Compensation 90,000 148,000
Other Long Term Liabilities 266,000 282,000
Capital Lease Obligation 3,525,000 3,601,000
- --------------------------------------------------------------------------------
TOTAL LONG-TERM LIABILITIES 3,964,000 4,274,000
- --------------------------------------------------------------------------------
SHAREHOLDERS' EQUITY
Preferred Stock, $1.00 par value, authorized
and unissued-1,000,000 shares -- --
Class A Common Stock, $1.00 par value,
22,000,000 shares authorized; issued-
7,216,195 and 5,006,562 shares in
1995 and 1994, respectively 7,216,000 5,007,000
Class B Common Stock, $1.00 par value,
2,000,000 shares authorized; issued-
458,474 and 476,476 shares in
1995 and 1994, respectively 458,000 476,000
Additional paid-in capital 23,908,000 14,374,000
Deficit (11,179,000) (10,304,000)
- --------------------------------------------------------------------------------
20,403,000 9,553,000
Equity adjustment from foreign currency
translation (142,000) (122,000)
- --------------------------------------------------------------------------------
TOTAL SHAREHOLDERS' EQUITY 20,261,000 9,431,000
- --------------------------------------------------------------------------------
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $28,005,000 $17,609,000
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
</TABLE>
See Notes to Consolidated Financial Statements.
20
<PAGE>
BASE TEN SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, 1995 1994 1993
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
REVENUES
Sales $17,841,000 $18,698,000 $21,829,000
Other 466,000 584,000 433,000
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
18,307,000 19,282,000 22,262,000
- ------------------------------------------------------------------------------------------------------------------------------
COST AND EXPENSES:
Cost of sales 11,813,000 12,996,000 14,958,000
Research and development 863,000 887,000 403,000
Selling, general and administrative 6,426,000 5,131,000 5,147,000
Interest 554,000 209,000 289,000
- ------------------------------------------------------------------------------------------------------------------------------
19,656,000 19,223,000 20,797,000
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
EARNINGS/(LOSS) BEFORE INCOME TAXES (1,349,000) 59,000 1,465,000
INCOME TAX (BENEFIT)/PROVISION (474,000) 24,000 507,000
- ------------------------------------------------------------------------------------------------------------------------------
NET EARNINGS/(LOSS) $ (875,000) 35,000 $ 958,000
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
NET EARNINGS/(LOSS) PER COMMON SHARE:
PRIMARY:
NET EARNINGS/(LOSS) $ (.13) $ .03 $ .18
NET EARNINGS/(LOSS) PER COMMON SHARE:
FULLY DILUTED:
NET EARNINGS/(LOSS) $ (.13) $ .03 $ .17
- ------------------------------------------------------------------------------------------------------------------------------
</TABLE>
See Notes to Consolidated Financial Statements.
21
<PAGE>
BASE TEN SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
EQUITY
ADJUSTMENT
ADDITIONAL FROM FOREIGN
CLASS A CLASS B PAID-IN CURRENCY TREASURY
SHARES AMOUNT SHARES AMOUNT CAPITAL (DEFICIT) TRANSLATION STOCK
- ----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
BALANCE:
October 31, 1992 2,953,557 $2,953,000 641,012 $641,000 $9,811,000 ($11,297,000) ($134,000) --
Conversions of
Class B Common to
Class A Common 156,939 157,000 (156,939) (157,000) -- -- -- --
Exercise of Options 194,102 194,000 74,038 74,000 397,000 -- -- (42,428)
Exercise of Rights 1,037,160 1,037,000 -- -- 1,409,000 -- -- --
Exercise of Warrants 345,700 346,000 -- -- 1,627,000 -- -- --
Issuance of Common
Stock 1,640 2,000 -- -- 9,000 -- -- --
Foreign currency
translation -- -- -- -- -- -- (28,000) --
Retirement of
treasury stock (42,428) (42,000) -- -- -- -- -- 42,428
Net Earnings/(Loss) -- -- -- -- -- 958,000 -- --
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
BALANCE:
October 31, 1993 4,646,670 4,647,000 558,111 558,000 13,253,000 (10,339,000) (162,000) --
Conversions of
Class B Common to
Class A Common 81,635 82,000 (81,635) (82,000) -- -- -- --
Exercise of Options 87,561 88,000 -- -- 185,000 -- -- (13,631)
Exercise of Rights 305 -- -- -- -- -- -- --
Exercise of Warrants 204,022 204,000 -- -- 936,000 -- -- --
Foreign currency
translation -- -- -- -- -- -- 40,000 --
Retirement of
treasury stock (13,631) (14,000) -- -- -- -- -- 13,631
Net Earnings/(Loss) -- -- -- -- -- 35,000 -- --
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
BALANCE:
October 31, 1994 5,006,562 5,007,000 476,476 476,000 14,374,000 (10,304,000) (122,000) --
Conversions of
Class B Common to
Class A Common 20,896 21,000 (20,896) (21,000) -- -- -- --
Exercise of Options 123,131 123,000 5,000 5,000 400,000 -- -- (13,743)
Exercise of Rights 828,542 828,000 -- -- 3,444,000 -- -- --
Exercise of Warrants 1,248,701 1,249,000 -- -- 5,690,000 -- -- --
Foreign currency
translation -- -- -- -- -- -- (20,000) --
Retirement of
treasury stock (11,637) (12,000) (2,106) (2,000) -- -- -- 13,743
Net Earnings/(Loss) -- -- -- -- -- (875,000) -- --
- -----------------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------------
BALANCE:
October 31, 1995 7,216,195 $7,216,000 458,474 $458,000 $23,908,000 $(11,179,000) $(142,000) --
- -----------------------------------------------------------------------------------------------------------------------------------
</TABLE>
See Notes to Consolidated Financial Statements.
22
<PAGE>
BASE TEN SYSTEMS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, 1995 1994 1993
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings/(loss) $ (875,000) $ 35,000 $ 958,000
ADJUSTMENTS TO RECONCILE NET EARNINGS TO NET CASH (USED IN)/
PROVIDED FROM OPERATING ACTIVITIES:
Depreciation and amortization 1,106,000 586,000 671,000
Deferred gain on sale of building (17,000) (282,000) --
Deferred income taxes (149,000) (290,000) 187,000
Accounts receivable (2,116,000) 228,000 (1,527,000)
Inventories (740,000) (269,000) 411,000
Other current assets (237,000) 303,000 148,000
Accounts payable and accrued expenses 162,000 (398,000) (408,000)
Deferred compensation (58,000) (23,000) (14,000)
Other assets (2,696,000) (2,171,000) (378,000)
Income taxes payable (325,000) 314,000 316,000
- ------------------------------------------------------------------------------------------------------------------------------
NET CASH PROVIDED (USED IN)/FROM OPERATIONS (5,945,000) (1,967,000) 364,000
- ------------------------------------------------------------------------------------------------------------------------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant and equipment - net (350,000) (306,000) (479,000)
Proceeds from sale of land and building -- 3,600,000 --
- ------------------------------------------------------------------------------------------------------------------------------
NET CASH (USED IN)/PROVIDED FROM INVESTING ACTIVITIES (350,000) 3,294,000 (479,000)
- ------------------------------------------------------------------------------------------------------------------------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of amounts borrowed (34,000) (4,711,000) (1,855,000)
Proceeds from the issuance of common stock 11,725,000 1,399,000 5,053,000
- ------------------------------------------------------------------------------------------------------------------------------
NET CASH PROVIDED FROM/(USED IN) FINANCING ACTIVITIES 11,691,000 (3,312,000) 3,198,000
- ------------------------------------------------------------------------------------------------------------------------------
Effect of Exchange Rate Changes on Cash (43,000) 50,000 (16,000)
- ------------------------------------------------------------------------------------------------------------------------------
NET INCREASE/(DECREASE) IN CASH 5,353,000 (1,935,000) 3,067,000
CASH, beginning of year 1,868,000 3,803,000 736,000
- ------------------------------------------------------------------------------------------------------------------------------
CASH, end of year $ 7,221,000 1,868,000 $ 3,803,000
- ------------------------------------------------------------------------------------------------------------------------------
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the year for interest $ 527,000 $ 173,000 $ 259,000
- ------------------------------------------------------------------------------------------------------------------------------
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Retirement of Treasury Stock $ 14,000 $ 14,000 $ 42,000
- ------------------------------------------------------------------------------------------------------------------------------
</TABLE>
See Notes to Consolidated Financial Statements
23
<PAGE>
BASE TEN SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED OCTOBER 31, 1995, 1994 AND 1993
A. DESCRIPTION OF BUSINESS
Base Ten Systems, Inc. and subsidiaries ("Base Ten" or the "Company")
designs and manufactures proprietary weapons control systems employing
microprocessors and advanced software for use in military aircraft and builds
custom designed electronic assemblies as a subcontractor to prime government
contractors. In addition, the Company develops batch processing control,
medical screening and image archiving software and designs and builds
proprietary electronic systems for use in secure communications.
B. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
1. BASIS OF PRESENTATION - The Company's consolidated financial statements
have been prepared on an historical cost basis.
2. PRINCIPLES OF CONSOLIDATION - The consolidated financial statements
include the accounts of Base Ten. All significant intercompany accounts,
transactions and profits have been eliminated.
3. REVENUE RECOGNITION - Earnings on long-term contracts are recognized on
the percentage-of-completion or unit-of-delivery basis. On contracts where the
percentage-of-completion method is used, costs and estimated earnings in excess
of progress billings are presented as unbilled receivables. Unbilled costs on
unit-of-delivery contracts are included in inventory. Payments received in
excess of costs incurred on long-term contracts are recorded as customers'
advance payments, which are included as a reduction of inventory on the balance
sheet.
4. INVENTORIES - Inventories are stated at the lower of cost (first-in,
first-out method) or market.
Inventoried costs on contracts include direct material, labor and
applicable overhead. In accordance with industry practice, inventoried costs
include amounts relating to contracts with a long production cycle, some of
which are not expected to be realized within one year.
5. PROPERTY, PLANT AND EQUIPMENT - Property, plant and equipment are carried
at cost and depreciated over estimated useful lives, principally on the
straight-line method. The estimated useful lives used for the determination of
depreciation and amortization are:
Leased asset - building 15 years
Machinery and equipment 3 to 10 years
Furniture and fixtures 3 to 20 years
6. OTHER ASSETS - Included in other non-current assets are software
development costs capitalized in accordance with Statement of Financial
Accounting Standard No. 86, "Accounting for Costs for Computer Software to be
Sold, Leased or Otherwise Marketed". As of October 31, 1995 and 1994,
capitalized software development costs (net of amortization) were $3,773,000 and
2,070,000, respectively. Amortization is computed on an individual product
basis and is the greater of (a) the ratio of current gross revenues for a
product to the total current and anticipated future gross revenues for that
product or (b) the straight-line method over the estimated economic life of the
product of four to five years. For the year ended October 31, 1995,
amortization of software development costs was $630,000.
24
<PAGE>
7. ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Included in accounts payable and
accrued expenses are accrued vacation costs aggregating $122,000 and $486,000 in
fiscal 1995 and 1994, respectively, accrued payroll of $347,000 and $271,000 in
fiscal 1995 and 1994, respectively, and accounts payable of $1,340,000 and
$1,078,000 in fiscal 1995 and 1994, respectively. The decrease in accrued
vacation cost is primarily due to a one time reduction in vacation entitlement
in fiscal 1995.
8. STATEMENT OF CASH FLOWS - For the purposes of the statement of cash
flows, the Company considers all investments with a maturity of three months or
less at date of acquisition to be cash equivalents.
9. RECENTLY ISSUED ACCOUNTING STANDARD - In October 1995, the Financial
Accounting Standards Board issued Statement of Financial Accounting Standards
No. 123, "Accounting for Stock-Based Compensation," which requires adoption of
the disclosure provisions no later than fiscal years beginning after December
15, 1995 and adoption of the recognition and measurement provisions for
nonemployee transactions no later than after December 15, 1995. The new
standard defines a fair value method of accounting for stock options and other
equity instruments. Under the fair value method, compensation cost is measured
at the grant date based on the fair value of the award and is recognized over
the service period, which is usually the vesting period.
Pursuant to the new standard, companies are encouraged, but are not
required, to adopt the fair value method of accounting for employee stock-based
transactions. Companies are also permitted to continue to account for such
transactions under Accounting Principles Board Opinion No. 25, "Accounting for
Stock Issued to Employees," but would be required to disclose in a note to the
financial statements pro forma net income and, if presented, earnings per share
as if the Company had applied the new method of accounting.
The accounting requirements of the new method are effective for all
employee awards granted after the beginning of the fiscal year of adoption. The
Company has not yet determined if it will elect to change to the fair value
method, nor has it determined the effect the new standard will have on net
income and earnings per share should it elect to make such a change. Adoption
of the new standard will have no effect on the Company's cash flows.
10. EMPLOYEE LOANS - The Company has loans amounting to $406,000 due from each
of its Corporate and Divisional Officers which will be repaid monthly including
interest at 6.5% beginning February, 1996 through January 31, 1999.
C. INVENTORIES
<TABLE>
<CAPTION>
---------------------------------------------------------------------
OCTOBER 31, 1995 1994
---------------------------------------------------------------------
<S> <C> <C>
Raw materials $1,557,000 $1,795,000
Work in progress 1,515,000 848,000
Finished goods 95,000 110,000
---------------------------------------------------------------------
3,167,000 2,753,000
Less advance payments 16,000 342,000
---------------------------------------------------------------------
$3,151,000 $2,411,000
---------------------------------------------------------------------
</TABLE>
25
<PAGE>
D. PROPERTY, PLANT AND EQUIPMENT
<TABLE>
<CAPTION>
---------------------------------------------------------------------
OCTOBER 31, 1995 1994
---------------------------------------------------------------------
<S> <C> <C>
Leasehold improvement $ 21,000 $ --
Machinery and equipment 8,853,000 8,581,000
Furniture and fixtures 617,000 608,000
Leased asset - land and building 3,600,000 3,600,000
---------------------------------------------------------------------
13,091,000 12,789,000
Less accumulated depreciation 8,611,000 8,207,000
---------------------------------------------------------------------
$ 4,480,000 $ 4,582,000
---------------------------------------------------------------------
</TABLE>
Maintenance and repairs charged to costs and expenses amounted to $240,000,
$239,000 and $353,000 in fiscal 1995, 1994 and 1993, respectively.
E. INCOME TAXES
INCOME TAXES - Effective November 1, 1993, the Company adopted Statement
of Financial Accounting Standards No. 109, "Accounting for Income Taxes" (SFAS
109), which requires a change from the deferred method's income statement
approach of accounting for income taxes to an asset and liability approach of
accounting for income taxes. Under the asset and liability approach, deferred
tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts of
existing assets and liabilities and their respective tax bases. This change had
no effect on the Company's statement of operations.
The provision (benefit) for income taxes includes the following:
<TABLE>
<CAPTION>
YEAR ENDED OCTOBER 31, 1995 1994 1993
-------------------------------------------------------------------
<S> <C> <C> <C>
Current:
Federal $(325,000) $259,000 $275,000
State -- 55,000 41,000
Foreign -- -- --
-------------------------------------------------------------------
Total Current (325,000) 314,000 316,000
-------------------------------------------------------------------
-------------------------------------------------------------------
Deferred:
Federal (124,000) (239,000) 191,000
State (25,000) (51,000) --
Foreign -- -- --
-------------------------------------------------------------------
Total Deferred (149,000) (290,000) 191,000
-------------------------------------------------------------------
-------------------------------------------------------------------
$(474,000) $24,000 $507,000
-------------------------------------------------------------------
</TABLE>
26
<PAGE>
A reconciliation of the Company's effective rate to the U.S. statutory rate
is as follows:
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, PERCENTAGE OF PRE-TAX EARNINGS
-------------------------------------
1995 1994 1993
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Federal tax (benefit)/provisions at applicable statutory rates (34.0%) 34.0% 34.0%
Increases (decreases) in income taxes resulting from:
State tax benefit, net of Federal tax effect (4.0) 7.0 1.0
Net changes in current and deferred valuation allowances 6.9 -- --
Other, net (4.0) -- --
- ------------------------------------------------------------------------------------------------------------------------------
(35.1%) 41.0% 35.0%
- ------------------------------------------------------------------------------------------------------------------------------
</TABLE>
The components of the deferred tax assets and liabilities as follows:
<TABLE>
<CAPTION>
--------------------------------------------------------------------
OCTOBER 31, OCTOBER 31,
1995 1994
--------------------------------------------------------------------
<S> <C> <C>
CURRENT
Vacation $ 46,000 $ 25,000
Deferred compensation 34,000 59,000
Other 3,000 10,000
--------------------------------------------------------------------
Total current assets 83,000 94,000
--------------------------------------------------------------------
--------------------------------------------------------------------
NONCURRENT
Deferred gain on sale leaseback $ 101,000 $ 111,000
Depreciation (315,000) (354,000)
Net operating loss carryforwards 681,000 --
Research and development
and investment tax credits
carryforwards 528,000 500,000
Valuation allowance (1,078,000) (500,000)
--------------------------------------------------------------------
Total noncurrent liabilities $ (83,000) $(243,000)
--------------------------------------------------------------------
--------------------------------------------------------------------
</TABLE>
The research and development and investment tax credits and the net
operating loss carryforward are available to offset future taxable earnings of
the Company. SFAS No. 109 requires that a valuation allowance be created and
offset against the deferred tax assets if, based on existing facts and
circumstances, it is more likely than not that some portion or all of the
deferred asset will not be realized. The valuation allowance will be adjusted
when the credits are realized or when, in the opinion of management, sufficient
additional positive evidence exists regarding the likelihood of their
realization. The reductions, if any, will be reflected as a component of income
tax expense.
The total current amounts presented above are included in other current
assets on the balance sheet.
The components of earnings/(loss) before income taxes were as follows:
<TABLE>
<CAPTION>
- -----------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, 1995 1994 1993
- -----------------------------------------------------------------------------
<S> <C> <C> <C>
Domestic $(1,343,000) $ 79,000 $1,377,000
Foreign (6,000) (20,000) 88,000
- -----------------------------------------------------------------------------
$(1,349,000) $59,000 $1,465,000
- -----------------------------------------------------------------------------
</TABLE>
27
<PAGE>
F. NET EARNINGS/(LOSS) PER SHARE
Primary and fully diluted earnings per share for fiscal years ended October
31, 1995, 1994 and 1993 were calculated using the following number of weighted
average common shares outstanding:
-------------------------------------------------------------------
1995 1994 1993
-------------------------------------------------------------------
Primary 6,925,744 7,568,681 7,131,135
Fully Diluted 6,925,744 7,568,927 7,135,538
-------------------------------------------------------------------
Primary and fully diluted earnings per common share were computed based on
the assumption that certain dilutive stock options were exercised for the years
ended October 31, 1994 and 1993. The dilutive effect of the stock options,
warrants and rights was determined using the modified treasury stock method in
1994 and 1993.
The stock options warrants and rights would have an anti-dilutive effect on
earnings per share for the year ended October 31, 1995 and therefore were not
included in the calculation of weighted average shares outstanding for both
primary and fully diluted earnings per share.
G. GEOGRAPHIC AND SEGMENT INFORMATION
The following tabulation details the Company's operations in different
geographic areas for the years ended October 31, 1993, 1994 and 1995.
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------
UNITED
STATES EUROPE ELIMINATIONS CONSOLIDATED
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
YEAR ENDED OCTOBER 31, 1993:
Revenues from unaffiliated sources $22,085,000 $177,000 $ -- $22,262,000
- ------------------------------------------------------------------------------------------------------------------------------
Operating profit $ 1,666,000 $ 88,000 $ -- $ 1,754,000
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets at October 31, 1993: $17,297,000 $536,000 $ (578,000) $17,255,000
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, 1994:
Revenues from unaffiliated sources $19,268,000 $ 14,000 $ -- $19,282,000
- ------------------------------------------------------------------------------------------------------------------------------
Operating profit/loss $ 288,000 $(20,000) $ -- $ 268,000
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets at October 31, 1994: $17,664,000 $398,000 $ (453,000) $17,609,000
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
YEAR ENDED OCTOBER 31, 1995:
Revenues from unaffiliated sources $17,925,000 $382,000 $ -- $18,307,000
- ------------------------------------------------------------------------------------------------------------------------------
Operating loss $ (789,000) $ (6,000) $ -- $ (795,000)
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets at October 31, 1995: $28,063,000 $960,000 $(1,018,000) $28,005,000
- ------------------------------------------------------------------------------------------------------------------------------
</TABLE>
28
<PAGE>
The Company's business is composed of two industry segments: government
technology and medical technology. A summary of information relating to these
divisions is presented below for the year ended October 31, 1995. Prior to
1995, the Medical Technology Division was considered insignificant and therefore
not presented.
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------------------------------------
GOVERNMENT MEDICAL
TECHNOLOGY TECHNOLOGY OTHER CONSOLIDATED
SEGMENT SEGMENT
- ------------------------------------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
YEAR ENDED OCTOBER 31, 1995:
Revenues $15,597,000 $ 2,244,000 $ 466,000 $18,307,000
- ------------------------------------------------------------------------------------------------------------------------------
Operating profit (loss): $ 1,017,000 $(2,278,000) $ 466,000 $ (795,000)
- ------------------------------------------------------------------------------------------------------------------------------
Identifiable assets at October 31, 1995: $11,433,000 $ 7,003,000 $9,569,000 $28,005,000
- ------------------------------------------------------------------------------------------------------------------------------
Depreciation and amortization: $ 257,000 $ 685,000 $ 164,000 $ 1,106,000
- ------------------------------------------------------------------------------------------------------------------------------
Capital expenditures: $ 118,000 $ 218,000 $ 14,000 $ 350,000
- ------------------------------------------------------------------------------------------------------------------------------
</TABLE>
Operating profit (loss) includes all revenues and expenses of the
reportable segment, except for interest income, dividend income, other income
and exchange losses. These items are shown as part of the "other."
Identifiable assets are assets used in the operation of each segment.
Other identifiable assets consist primarily of cash and assets that are
corporate owned.
Total Government Technology sales in the amounts of $4,633,000, $4,289,000
and $3,825,000 in fiscal 1995, 1994 and 1993, respectively, were made to a
single European customer. All sales were export sales and are included in the
United States sales to unaffiliated customers. In 1995, three domestic
customers accounted for sales of $3,540,000, $1,619,000 and $1,037,000,
respectively. As provided in several contracts, customers advance funds to the
Company for the purpose of purchasing inventory. The related advances have been
offset against these inventories.
H. COMMITMENTS
CHANGE IN CONTROL. The Company has agreements with three of its executive
officers providing severance payments if the executive's employment is
terminated within three years after a change in control of the Company (i) by
the Company for reasons other than death, disability or cause or (ii) by the
executive for good reason. The amount of the severance payment is 2.99 times
total average compensation and cost of employee benefits for each of the five
years prior to the change in control, subject to a maximum equal to the amount
deductible by the Company under the Internal Revenue Code.
EMPLOYMENT AGREEMENTS. The Company has employment agreements with four key
employees. Three of the agreements provide for one year of compensation in the
aggregate of $600,000 plus normal benefits and any amounts due under incentive
compensation plans in the event the employee is terminated without cause. The
fourth agreement provides for a lump sum payment in the amount of $150,000 in
the event of retirement subsequent to October 31, 1996.
CONSULTING AGREEMENT. The Company has a consulting agreement providing one
of its directors compensation in the amount of $230,000 in fiscal 1996 and
$155,000 in fiscal 1997 for technical and marketing services. This agreement is
cancelable with three months notice by either party and expires on May 31, 1998.
29
<PAGE>
LEASES. The Company entered into a sale and leaseback arrangement on
October 28, 1994. Under the arrangement, the Company sold its main building in
Trenton, New Jersey and agreed to lease it back for a period of 15 years under
terms that qualify the arrangement as a capital lease. The buyer/lessor of the
building was a partnership, one of the partners of which is an officer and
director of the Company. In addition, a non-interest bearing security deposit
of $550,000 was paid at closing and included in other non-current assets on the
balance sheet. Interest is calculated under the effective interest method and
depreciation is taken using the straight line method over the term of the lease.
The Company's future minimum lease payments related to the sale-leaseback
arrangement in effect at October 31, 1995 are as follows:
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Fiscal
1996 $ 560,000
1997 560,000
1998 560,000
1999 560,000
2000 615,000
2001 and thereafter 5,971,000
-----------
8,826,000
Less interest portion (5,259,000)
-----------
Present value of net minimum payments $ 3,567,000
-----------
-----------
I. DEFERRED COMPENSATION PLANS
The Company has a non-qualified deferred compensation plan that provides
for compensation payments to a key individual. Distributions are made five
years after amounts are earned.
J. STOCK OPTION PLANS, WARRANTS AND RIGHTS
The Company's 1990 Incentive Stock Option Plan reserves 484,000 shares of
either Class A or Class B Common Stock for purchase upon the exercise of options
that may be granted at not less than the fair market value as of the date of
grant and that are exercisable over a period not to exceed ten years. There are
no options available for grant under this plan.
The Company's 1992 Stock Option Plan reserves 700,000 shares of Class A
Common Stock for purchase upon the exercise of options. Approximately 44,000
options remain available for grant under this plan. Options may not be granted
at less than fair market value as of the date of grant and are exercisable over
a period not to exceed ten years.
The Company's discretionary compensation plan reserves 400,000 shares of
Class A Common Stock for issuance upon the exercise of options. Approximately
34,000 options remain available for grant under this plan. Options may not be
granted at less than fair market value as of the date of grant and are
exercisable over a period not to exceed ten years.
30
<PAGE>
J. STOCK OPTION PLANS, WARRANTS AND RIGHTS (CONTINUED)
Information with respect to the aforementioned stock option plans is
summarized as follows:
<TABLE>
<CAPTION>
---------------------------------------------------------------------------------------------------------------------------
Class A Class B Total
---------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Outstanding at October 31, 1992
($1.25 to $11.59 per share) 607,305 83,984 691,289
Granted ($7.00 to $8.875 per share) 176,300 -- 176,300
Exercised ($1.25 to $4.00 per share) (194,102) (74,038) (268,140)
Canceled ($3.00 per share) (172) -- (172)
---------------------------------------------------------------------------------------------------------------------------
Outstanding at October 31, 1993
($3.00 to $11.59 per share) 589,331 9,946 599,277
Granted ($7.93 per share) 400,170 -- 400,170
Exercised ($3.00 to $8.625 per share) (87,561) -- (87,561)
Canceled ($8.00 - $8.625 per share) (31,450) -- (31,450)
Expired ($10.00 to $11.59) (2,182) -- (2,182)
---------------------------------------------------------------------------------------------------------------------------
Outstanding at October 31, 1994
($3.00 to $8.875 per share) 868,308 9,946 878,254
Granted ($6.625 to $11.25 per share) 46,000 -- 46,000
Exercised ($3.00 to $8.625 per share) (104,431) (5,000) (109,431)
Canceled ($8.625 per share) (26,483) -- (26,483)
---------------------------------------------------------------------------------------------------------------------------
Outstanding at October 31, 1995
($3.00 to $11.25 per share) 783,394 4,946 788,340
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
Exercisable at October 31, 1995 753,393 4,946 758,339
---------------------------------------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------------------------------------
</TABLE>
The Company has issued 665,000 warrants and 332,000 options to consultants
and three non-management directors who at prices ranging from $3.00 to $9.375,
expiring from 1997 to 2004. One consultant and one director have exercised
warrants or options for a total of 20,000 shares during fiscal 1995 at prices
ranging from $3.4375 to $7.25 per share. None of these warrants or options have
expired to date. Included in the above are 250,000 warrants issued to
consultants for services related to the promotion and selling of the Company's
stock at an exercise price which was less than the fair market value of the
stock at the date of grant. The remaining options and warrants were issued at
fair market value at the date of grant.
During fiscal 1995, the Board of Directors issued options to various
employees to purchase a total of 75,000 shares of Class A Common Stock. The
options have exercise prices ranging from $7.25 to $8.50 per share (fair market
value at the date of grant) and expire in 2000.
31
<PAGE>
The Company has adopted a 1995 Incentive Stock Option Plan subject to
shareholder approval at the 1996 Annual Meeting of Shareholders. The plan
reserves 750,000 shares of Class A Common Stock. Options may not be granted at
less than fair market value as of the date of grant and are exercisable over a
period not to exceed ten years. In October, 1995, the Company granted to
employees options to purchase 420,050 Class A Common Shares at either $10 7/8 or
11 15/16 per share (fair market value at the date of grant), exercisable at
various rates through 2005.
K. EMPLOYEE BENEFIT PLAN
In 1986, the Company adopted a benefit plan under section 401(k) of the
Internal Revenue Code. In 1992, the plan was amended to discontinue the
Company's contribution. The plan allows all employees to defer up to 17% of
their pre-tax income through contributions to the plan.
32
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized, this ___ day of
January, 1996.
BASE TEN SYSTEMS, INC.
By: /S/ MYLES M. KRANZLER By: /S/ EDWARD J. KLINSPORT
---------------------- ------------------------
Myles M. Kranzler Edward J. Klinsport
Chief Executive Officer Chief Financial Officer
By: /S/ SUSAN M. KLINSPORT
-----------------------
Susan M. Klinsport
Principal Accounting Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant in the capacities and on the date indicated.
TITLE DATE
Myles M. Kranzler, James A. Eby, Directors
Edward J. Klinsport, Alan J. Eisenberg,
Alexander M. Adelson, Donald M. Daniels,
Alan S. Poole*
By: /S/ EDWARD J. KLINSPORT January __, 1996
-----------------------------------------
*Edward J. Klinsport, as attorney-in-fact
33
<PAGE>
EXHIBIT INDEX
EXHIBIT
NUMBER EXHIBIT PAGE
- ------ ------- ----
3. (a) Restated Certificate of Incorporation, as amended, of *
Registrant (incorporated by reference to Exhibit 4(a) to
Amendment No. 1 to Registrant's Registration Statement on
Form S-8 (File No. 2-84451) filed on July 31, 1990).
(b) Certificate of Amendment of the Restated Certificate of *
Incorporation dated September 1, 1992 (incorporated by
reference to Exhibit 4(b)(2) to Amendment No. 3 to
Registrant's Registration Statement on Form S-1 (File No.
33-48404) filed on September 3, 1992).
(c) Amended By-Laws of the Registrant (incorporated by *
reference to Exhibit 4(d)(2) to Registrant's Registration
Statement on Form S-8 (File No. 33-60454) filed on April
1, 1993).
4. (a) Warrant Agreement dated February 24, 1989 among the *
Registrant, F.N. Wolf & Co., Inc. and American Stock
Transfer & Trust Company (incorporated by reference to
Exhibit 4.4 to Amendment No. 3 to Registrant's
Registration Statement on Form S-2 (File No. 33-25302-01)
filed on February 15, 1989).
(b) Form of Warrant certificate (included in Exhibit 4(a) *
hereto).
10. (a) 1980 Deferred Compensation Agreement between the * (A)
Registrant and certain executive officers (incorporated by
reference to Exhibit 10.3 to Registrant's Registration
Statement on Form S-1 File No. 2-70259 filed on December
16, 1980).
(b) 1981 Incentive Stock Option Plan of Registrant, as amended * (A)
and restated on January 12, 1990 (incorporated by
reference to Exhibit 4(c) to Amendment No. 1 to
Registrant's Registration Statement on Form S-8 (File No.
2-84451) filed on July 31, 1990).
(c) 1992 Stock Option Plan of Registrant (incorporated by * (A)
reference to Exhibit 10(ai) to Amendment No. 3 to
Registrant's Registration Statement on Form S-1 (File No.
33-48404) filed on September 3, 1992).
(d) Change in Control Agreement dated October 23, 1991 between * (A)
Registrant and Myles M. Kranzler (incorporated by
reference to Exhibit 10(e) to Registrant's Annual Report
on Form 10-K (File No. 0-7100) for the fiscal year ended
October 31, 1991).
(e) Change in Control Agreement dated October 23, 1991 between * (A)
Registrant and James A. Eby (incorporated by reference to
Exhibit 10(f) to Registrant's Annual Report on Form 10-K
(File No. 0-7100) for the fiscal year ended October 31,
1991).
(f) Change in Control Agreement dated October 23, 1991 between * (A)
Registrant and Edward J. Klinsport (incorporated by
reference to Exhibit 10(h) to Registrant's Annual Report
on Form 10-K (File No. 0-7100) for the fiscal year ended
October 31, 1991).
34
<PAGE>
EXHIBIT
NUMBER EXHIBIT PAGE
- ------ ------- ----
(g) Employment Agreement dated as of March 26, 1992 between * (A)
the Registrant and Myles M. Kranzler (incorporated by
reference to Exhibit 28(b) to Registrant's Current Report
on Form 8-K (File No. 0-7100) filed on April 10, 1992).
(h) Employment Agreement dated as of March 26, 1992 between * (A)
the Registrant and James A. Eby (incorporated by reference
to Exhibit 28(c) to Registrant's Current Report on Form 8-
K (File No. 0-7100) filed on April 10, 1992).
(i) Employment Agreement dated as of March 26, 1992 between * (A)
the Registrant and Edward J. Klinsport (incorporated by
reference to Exhibit 28(d) to Registrant's Current Report
on Form 8-K (File No. 0-7100) filed on April 10, 1992).
(j) Employment Agreement dated as of March 26, 1992 between * (A)
the Registrant and Alan J. Eisenberg (incorporated by
reference to Exhibit 28(e) to Registrant's Current Report
on Form 8-K (File No. 0-7100) filed on April 10, 1992).
(k) Amended Agreement dated July 28, 1992 between the * (A)
Registrant and Alexander Adelson (incorporated by
reference to Exhibit 10(ar) to the Registrant's
Registration Statement on Amendment No. 3. to Form S-2 on
Form S-1 (Registration No. 33-48404) filed on September 3,
1992).
(l) Modification of Amended Agreement dated January 11, 1993
between the Registrant and Alexander M. Adelson.
(m) Amended Modification of Amended Agreement dated January
28, 1994 between the Registrant and Alexander M. Adelson.
(n) Amended Consulting Agreement made as of February 24, 1992 * (A)
between the Registrant and Bruce D. Cowen (incorporated by
reference to Exhibit 10(as) to the Registrant's
Registration Statement on Amendment No. 3. to Form S-2 on
Form S-1 (Registration No. 33-48404) filed on September 3,
1992).
(o) Modification of Amendment Agreement dated January 11, 1993
between the Registrant and Bruce D. Cowen.
(p) Consulting Agreement dated March 1, 1994 between the
Registrant and Bruce D. Cowen.
(q) Option Agreement dated as of November 9, 1992 between the * (A)
Registrant and Donald M. Daniels (incorporated by
reference to Exhibit 10(as) to the Registrant's Annual
Report on Form 10-K (File No. 0-7100) for the fiscal year
ended October 31, 1992).
(r) Option Agreement dated as of June 5, 1992 between the *
Registrant and Strategic Growth International, Inc.
(incorporated by reference to Exhibit 10(at) to the
Registrant's Annual Report on Form 10-K (File No. 0-7100)
for the fiscal year ended October 31, 1992).
(s) Acquisition Agreement dated October 28, 1994 between the *
Registrant and CKR Partners, L.L.C. (incorporated by
reference to Exhibit 2(a) to Registrant's Current Report
on Form 8-K (File No. 0-7100) dated November 11, 1994).
35
<PAGE>
EXHIBIT
NUMBER EXHIBIT PAGE
- ------ ------- ----
(t) Lease dated October 28, 1994 between the Registrant and *
CKR Partners, L.L.C. (incorporated by reference to Exhibit
2(b) to Registrant's Current Report on Form 8-K (File No.
0-7100) dated November 11, 1994).
21. Subsidiaries of the Registrant
23. Independent Auditors' Consent.
24. Power of Attorney
_______________
* Incorporated by reference.
(A) A management contract or compensatory plan or arrangement.
<PAGE>
BASE TEN SYSTEMS, INC.
EXHIBIT 21
SUBSIDIARIES OF REGISTRANT
The following are wholly-owned subsidiaries of the Registrant:
STATE OR JURISDICTION
NAME OR ORGANIZATION
- --------------------------------------------------------------------------------
Base Ten Aerospace and Communications, Inc. New Jersey (a)
Base Ten Software, Inc. New Jersey (a)
Base Ten Systems, Ltd. United Kingdom (a)
Base Ten of Canada, Ltd. Canada (b)
Base Ten Investment, Co. Delaware (b)
Base Ten International Sales, Ltd. Jamaica (a)
Base Ten Software, Ltd. Ireland (a)
- --------------------------------------------------------------------------------
(a) Financial statements included in Consolidated Financial Statements of
Registrant
(b) Dormant
<PAGE>
EXHIBIT 23.1
INDEPENDENT AUDITORS' CONSENT
The Board of Directors and Shareholders
Base Ten Systems, Inc.
Trenton, New Jersey 08619
We consent to the incorporation by reference in the Registration Statements No.
33-89712, No. 33-60454, No. 33-55752 and Amendment No. 1 to Registration
Statement No. 2-84451 of Base Ten Systems, Inc. and Subsidiaries on Form S-8 and
the Registration Statement No. 33-89710 of Base Ten Systems, Inc. and
Subsidiaries on Form S-3 of our report dated December 15, 1995, appearing in
this annual report on Form 10-K of Base Ten Systems, Inc. and Subsidiaries for
the year ended October 31, 1995.
DELOITTE & TOUCHE LLP
Parsippany, New Jersey
January 26, 1996
<PAGE>
EXHIBIT 24.1
POWER OF ATTORNEY
KNOWN ALL MEN BY THESE PRESENTS that each individual whose signature
appears below constitutes and appoints Myles M. Kranzler and Edward J.
Klinsport, and each of them, his true and lawful attorneys-in-fact and agents
with full power of substitution, for him and in his name, place and stead in any
and all capacities, to sign the Annual Report on Form 10-K of Base Ten Systems,
Inc. for the fiscal year ended October 31, 1995 and any amendments thereto, and
to file same, with all exhibits thereto, and all documents in connection
therewith, with the Securities and Exchange Commission, pursuant to Section 13
or 15(d) of the Securities Exchange Act of 1934, as amended, granting unto said
attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each and every act and thing requisite and necessary to be done to
comply with the provisions of the Securities Act of 1934, and all requirements
of the Securities and Exchange Commission, hereby ratifying and confirming all
that said attorneys-in-fact and agents or any of them, or their or his
substitutes, may lawfully do or cause to be done by virtue thereof.
/S/ MYLES M. KRANZLER
------------------------------
Myles M. Kranzler
/S/ JAMES A. EBY
------------------------------
James A. Eby
/S/ EDWARD J. KLINSPORT
------------------------------
Edward J. Klinsport
/S/ ALAN J. EISENBERG
------------------------------
Alan J. Eisenberg
/S/ DONALD M. DANIELS
------------------------------
Donald M. Daniels
/S/ ALEXANDER M. ADELSON
------------------------------
Alexander M. Adelson
/S/ ALAN S. POOLE
------------------------------
Alan S. Poole
/S/ SUSAN M. KLINSPORT
------------------------------
Susan M. Klinsport
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> OCT-31-1995
<PERIOD-START> NOV-01-1994
<PERIOD-END> OCT-31-1995
<CASH> 7,221,000
<SECURITIES> 0
<RECEIVABLES> 7,184,000
<ALLOWANCES> 0
<INVENTORY> 3,151,000
<CURRENT-ASSETS> 644,000
<PP&E> 4,480,000
<DEPRECIATION> 0
<TOTAL-ASSETS> 28,005,000
<CURRENT-LIABILITIES> 3,780,000
<BONDS> 0
0
0
<COMMON> 7,674,000
<OTHER-SE> 12,587,000
<TOTAL-LIABILITY-AND-EQUITY> 28,005,000
<SALES> 17,841,000
<TOTAL-REVENUES> 18,307,000
<CGS> 11,813,000
<TOTAL-COSTS> 19,656,000
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 554,000
<INCOME-PRETAX> (1,349,000)
<INCOME-TAX> (474,000)
<INCOME-CONTINUING> (875,000)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (875,000)
<EPS-PRIMARY> (.13)
<EPS-DILUTED> (.13)
</TABLE>
